VS-7375

Phase 2Small molecule

VS-7375 is one of 90 small molecule programs targeting Pancreatic Ductal Adenocarcinoma (PDAC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting

Non-Small Cell Lung CancerRecruiting

Solid TumorsRecruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Phase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Anktiva

SSWOG Cancer Research Network

Phase 3

1 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

VS-7375

VVerastem, Inc.

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Solid Tumors

NCT07020221

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT07659782

Phase 2Recruiting

Colorectal Cancer

NCT07659795

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07644559

Clinical

Trials by Indication[1]

Solid Tumors1 trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Recruiting·VVerastem, Inc.·Phase 1/2·NCT07020221·295 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

Recruiting·VVerastem, Inc.·Phase 2·NCT07659782·105 enrolled

Colorectal Cancer1 trial

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Recruiting·VVerastem, Inc.·Phase 2·NCT07659795·150 enrolled

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

Recruiting·VVerastem, Inc.·Phase 2·NCT07644559·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VS-7375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VS-7375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VS-7375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Verastem, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVerastem, Inc.

VS-7375

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Colorectal Cancer1 trial

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

References

Drug Info

Quick Facts

Related News